SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is drawing attention after a recent rebound that traders say held its gains, with bullish technical setups and positioning ahead of earnings. The upbeat view contrasts with concerns that high rates and a sluggish housing market could continue to weigh on renovation demand.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers sharp rally to fresh multi-year highs is drawing attention, with traders citing rotation into defensive, dividend-paying pharma stocks and positioning ahead of the quarterly report. Bulls see a technical breakout and pipeline momentum, while skeptics warn the move may meet resistance and point to patent-expiration and growth concerns.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,397.34014094 USD and is up 0.28 over the last 24 hours. It is currently trading on 12773 active market(s) with $12,152,377,915.37 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoin is drawing attention amid concerns over Binances reported major hack and paused withdrawals, with traders debating whether damaged exchange trust could trigger further selling. Others argue the market is absorbing the shock and point to Binances reported reimbursement progress and planned withdrawal reopening as reasons for optimism.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Attention centers on expected Q3 results and the Phase 3 QUILT-2.005 topline for ANKTIVA plus BCG in BCG-naive bladder cancer; the trial is database-locked, with a supplemental filing planned if results support it. Bullish traders see the readout and ANKTIVAs expanded bladder-cancer label as growth catalysts, while others question commercial uptake and point to competition, short-selling, and broader market weakness to explain the volatility.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is drawing attention as traders use the leveraged inverse Nasdaq ETF to hedge or bet on further weakness in tech, citing concerns about AI spending and valuations alongside recent tech-led selling. The community is divided: some expect more downside, while others warn that rumors of a U.S.Iran deal and a possible market rebound could reverse gains in the short ETF.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Dow is being discussed amid volatile, uneven trading across major indexes, with traders watching Fed policy and rising Treasury yields as pressures on equities. Some see relative strength in the Dow as money rotates away from tech, while others warn that inflation, oil-market risks and weakening momentum could deepen a selloff.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Discussion centers on BioCrysts upcoming quarterly results and whether continued ORLADEYO growth can support the stock despite its weak performance. Traders are also looking ahead to Navenibart and Netherton data, while debating managements acquisition strategy and expressing frustration over dilution and limited shareholder returns; buyout talk remains speculative.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results and outlook are drawing attention, with traders highlighting stronger streaming profitability and resilient theme-park performance. The reaction is mixed: some see support for a turnaround, while others point to the stocks persistent range-bound price action and difficulty holding gains.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is drawing attention ahead of its upcoming earnings report, with traders watching whether guidance holds and how management addresses pressure on the pharmacy benefit management business. Some see the recent pullback as a potential technical rebound setup, while others remain cautious after the stocks recent selling.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

A sharp volatility spike has lifted UVIX, drawing traders seeking a hedge against a broader market pullback. The community is split between expecting volatility to persistciting concerns about oil, interest rates and geopolitical risksand warning that UVIX can quickly lose value as volatility fades and its leveraged futures exposure decays.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is MIRA Pharmaceuticals Stock Gaining Tuesday?

MIRA Pharmaceuticals (NASDAQ: MIRA) stock jumps as MIRA-55 meets key preclinical study milestones for non-opioid inflammatory pain relief.read more...

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

Others

What's Going On With MIRA Pharma Stock Tuesday?

MIRA Pharmaceuticals (NASDAQ: MIRA) eyes IND submission for Mira-55 after new 2026 data confirms no CNS side effects.read more...

Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Drops By 13.9%

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) saw a significant decrease in short interest in February. As of February 27th, there was short interest totaling 489,206 shares, a decrease...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 29.4% in February

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 13th, there was short interest totaling...

MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Down 6.6% - Time to Sell?

MIRA Pharmaceuticals (NASDAQ:MIRA) Trading Down 6.6% - Time to Sell...

MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 6.6% - Time to Sell?

MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 6.6% - What's Next...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Sees Significant Growth in Short Interest

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Update

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling...

MIRA Pharmaceuticals (NASDAQ:MIRA) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of MIRA Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday...

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. It engages in developing its product candidates, Ketamir-2 and MIRA-55, designed to address unmet medical needs in pain management, depression, PTSD, and cognitive function. The company was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.

Mira Pharmaceuticals Inc

Mira Pharmaceuticals Stock Soars 70% After-Hours As Pain Drug Outperforms Morphine; Retail Sees ‘Blockbuster Drug’ In The Making

Equity

Extremely Bullish Sentiment

Shares of Mira Pharmaceuticals surged 70% after-hours on Wednesday after the company announced new preclinical data showing its oral drug candidate Mira-55 outperformed injected morphine in normalizing pain and reducing inflammation in an animal model of chronic inflammatory pain.The study, conducted as part of Mira’s Mira-55 program, found that the orally administered compound not only restored pain thresholds to baseline levels but also demonstrated strong anti-inflammatory effects, pointing to a dual action that morphine failed to match.&nbsp;The company said these findings will support its planned Investigational New Drug (IND) application for chronic inflammatory pain and reinforce its position in the $70 billion non-opioid pain market.Mira-55, a non-psychotropic marijuana analog, achieved full pain normalization and significantly reduced paw swelling, confirming a CB2 receptor-mediated anti-inflammatory mechanism. Morphine, by contrast, showed only partial inflammation reduction through indirect effects on the central nervous system.The company noted that this is the first study in the program to measure inflammation directly alongside pain. The oral efficacy of Mira-55 also offers clinical convenience compared with morphine, which requires injection to achieve similar pain control.On Stocktwits, retail sentiment for Mira was ‘extremely bullish’ amid a 7,000% surge in 24-hour message volume.One user on Stocktwits called it “absolutely insane” that a small biotech like Mira could claim Mira-55 outperforms morphine, saying it could draw major investors and even qualify for FDA fast-track review. The user highlighted that Mira-55’s oral delivery and CB2 receptor action were unheard of, adding that the $60 billion+ market gives the stock huge upside potential.&nbsp;<stembedurl>https://stocktwits.com/Moobumples/message/632515002</stembedurl>Another user said he sees potential in Mira-55 becoming a “blockbuster drug” and urged others to buy.<stembedurl>https://stocktwits.com/Intradaytrade100/message/632498480</stembedurl><a href="https://stocktwits.com/symbol/MIRA">Mira Pharmaceuticals’ stock</a> has risen 16% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mira Pharmaceuticals’ stock (MIRA) has risen 16% so far in 2025. (Photo credit: Getty Images)

The company said its oral treatment fully normalized pain and sharply reduced inflammation in preclinical studies, outperforming injected morphine. 

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.5485
Prev Close	$0.5716
Open	$0.589
Dividend Yield	0.00%
50-Day Moving Average	$0.7373
Beta	0.88
Avg. Volume	1.59M
PE Ratio	-0.40

52-Week High	$1.75
52-Week Low	$0.5101
Market Capitalization	$23.05M
EPS (Annual)	-$1.35
Price to Book	2.82
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

MIRA Fundamentals